Sagimet Biosciences Inc.

Sagimet Biosciences Inc.

Biotechnology • Healthcare • San Mateo, CA, United States • SGMT (NGM)

Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops novel therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic pathways in the United States. The company's lead drug candidate is Denifanstat, an oral, once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfunction-associated steatohepatitis. It also develops TVB-3567, a FASN inhibitor for the treatment of acne; and other oncology programs, such as various solid tumor and glioblastoma. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California.

650 561 8600 155 Bovet Road, San Mateo, CA 94402, United States

Stock Performance (90 Days)

Data through Dec 26, 2025
Layoff Events
Earnings Calls
Price updates on page refresh. Intraday quotes available during market hours (9:30 AM - 4:00 PM EST).

Layoff History

No layoff events recorded for this company.

Earnings Call Transcripts

View All →
Q4 2025 Neutral
Nov 13, 2025

Sagimet Biosciences Inc. (SGMT) furnished legal disclosures and announced an updated investor presentation on November 13, 2025. The provided transcript does not contain Q4 2025 financial results or operational highlights, making a performance assessment impossible.

Recent News

All You Need to Know About Sagimet Biosciences Inc. (SGMT) Rating Upgrade to Strong Buy - Yahoo Finance
Yahoo Finance • Oct 15
Sagimet Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
GlobeNewswire • Dec 9
Sagimet Biosciences Advances Denifanstat: Q3 Earnings And Upcoming Catalysts - Seeking Alpha
Seeking Alpha • Nov 18
Sagimet Biosciences (Nasdaq: SGMT) sees China partner’s acne drug NDA accepted by NMPA - Stock Titan
Stock Titan • Dec 10
Sagimet Biosciences stock price target raised to $35 by Citizens - Investing.com
Investing.com • Nov 14

Other Biotechnology Companies

View All →
CODEXIS, INC. logo Codexis, Inc.
1 layoff tracked
$144.5M market cap
VERTEX PHARMACEUTICALS INC / MA logo Vertex Pharmaceuticals Inc. / MA
$118.68B market cap
REGENERON PHARMACEUTICALS, INC. logo Regeneron Pharmaceuticals, Inc.
$82.72B market cap
ALNYLAM PHARMACEUTICALS, INC. logo Alnylam Pharmaceuticals, Inc.
$52.92B market cap
ARGENX SE logo Argenx SE
$52.62B market cap
INSMED Inc logo Insmed Inc.
$37.61B market cap

Frequently Asked Questions

Has Sagimet Biosciences Inc. had layoffs?
No layoff events have been recorded for Sagimet Biosciences Inc. in our database. This could mean the company has not conducted significant layoffs, or any layoffs have not been publicly reported.
How many employees does Sagimet Biosciences Inc. have?
Sagimet Biosciences Inc. has approximately 14 employees.
What industry is Sagimet Biosciences Inc. in?
Sagimet Biosciences Inc. operates in the Biotechnology industry, within the Healthcare sector.
Is Sagimet Biosciences Inc. a publicly traded company?
Yes, Sagimet Biosciences Inc. is publicly traded under the ticker symbol SGMT on the NGM. The company has a market capitalization of approximately $0.19 billion.
Where is Sagimet Biosciences Inc. headquartered?
Sagimet Biosciences Inc. is headquartered in San Mateo, CA, United States at 155 Bovet Road, San Mateo, CA 94402, United States.

Disclaimer

Data aggregated from public sources including WARN notices, SEC filings, press releases, and market data. While we strive for accuracy, information is provided "as-is" for informational purposes only. Always verify critical information with official company sources.

This information does not constitute investment, financial, legal, or career advice. See our Terms of Service, Privacy Policy, and About page for more information.

Found an error? Report it here.